The Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary

No new drugs have been given a voucher under the FDA’s fast-track review program since Marty Makary left the agency in May. According to internal documents and six sources familiar with the matter, the initiative has now been shelved. The shelving of the National Priority Voucher program has not been previously reported.

The Commissioner’s National Priority Voucher program was launched in June 2025, during the Trump administration. Its aim was to compress drug review timelines to as little as one to two months for therapies addressing national priorities, such as urgent unmet health needs. Once presented as a bold fix for U.S. pharmaceutical regulation, the initiative has effectively stalled.

Critics, however, pointed to possible preferential treatment for companies meeting Donald Trump’s demands, such as offering drugs at lower prices. The program has been left adrift, offering a stark window into the internal chaos, infighting, and lack of steady leadership that has plagued the FDA, which has been without a commissioner since May.